EGFR and neoplasm: Although the addition of cetuximab to erlotinib is insufficient to overcome erlotinib resistance in EGFR-driven lung adenocarcinoma [23], the clinical potential of dual-agent molecular targeting of the EGFR in patients with EGFR wild-type tumours remains to be elucidated and may represents an interesting research area to be pursued.